Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results Helix" or the " Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020. OVERVIEW The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 - $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020 included a gain from loss of control in Helix Immuno-Oncology S.A. ("HIO") of $2,162,000 (2019 - $nil) on September 3, 2020. On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ("CAIAC") to purchase the Company's remaining 29.89% holdings in Helix Immuno-Oncology S.A. ("HIO"), for gross proceeds of PLN 6,700,000 ($2,308,000). Closing of the transaction is to occur upon finalizing administrative reporting requirements and evidence of share registry changes in Poland. The Company expects to close the transaction in the very near term. A finder's fee is owed to ACM Establishment Management Est ("ACMest") upon closing of the transaction equal to 12.5% of the gross proceeds.